Researchers at the The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland studied the relationship between the change of PSA doubling time (PSADT) and disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer.

They retrospectively analyzed the data from 96 men diagnosed with biochemically relapsed prostate cancer (BRPC) who were treated with IAD. The IAD consisted of LHRH-agonists?±?antiandrogen given usually at PSA threshold (ng/ml) of 10-2